Advanced Oncotherapy (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, has told DirectorsTalk this morning that it will be hosting investor and analyst presentations in London on Monday 6 March 2017 and in Zürich, Switzerland the following day, Tuesday 7 March 2017.
The presentations will outline some of the key aspects of Advanced Oncotherapy’s technology, the clinical benefits of proton therapy and the key milestones for the manufacturing and commercialisation of LIGHT (Linac for Image Guided Hadron Therapy). These events are in relation to the initial 100 day review that has been conducted by CEO Nicolas Serandour, as announced upon his appointment on 27 October 2016.
The event in London will be held at the Royal Society of Medicine, 1 Wimpole St, W1G 0AE.
In Zürich, it will take place at the Baur au Lac hotel, Talstrasse 1, 8001, Switzerland. Both events will commence at 4pm local time and will be followed by drinks and canapés at 5.30pm.
The timetable for the event in London is as follows:
|
15:30 |
Registration
|
|
16:00 |
Introduction to Advanced Oncotherapy: From the Development of a World-Leading Technology to its Commercialisation
|
|
16:20
|
The Benefit of Proton Therapy: How to Make the Best Use of Proton Therapy in Today’s Treatments
|
|
16.35 |
The Advantages of the LIGHT System: Taking Advantage of a Linear Accelerator
|
|
16.50 |
Roadmap to Production and Conclusions
|
|
17.05 |
Q&As |
|
17.30 |
Drinks & canapés |
The event in Zürich will follow the same format, excluding registration.
To register and attend either presentation, or to receive further information on Advanced Oncotherapy, please contact Walbrook PR on 020 7933 8780 or email avo@walbrookpr.com.
